| 0.9425 -0.054 (-5.42%) | 08-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.22 | 1-year : | 1.43 |
| Resists | First : | 1.04 | Second : | 1.22 |
| Pivot price | 0.76  |
|||
| Supports | First : | 0.72 | Second : | 0.52 |
| MAs | MA(5) : | 0.94 |
MA(20) : | 0.71 |
| MA(100) : | 1.05  |
MA(250) : | 1.51 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.9 |
D(3) : | 86.3 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 3.06 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IVVD ] has closed below upper band by 17.5%. Bollinger Bands are 24% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.98 | 0.98 - 0.98 |
| Low: | 0.9 - 0.9 | 0.9 - 0.91 |
| Close: | 0.94 - 0.94 | 0.94 - 0.95 |
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Mon, 24 Aug 2026
Invivyd (IVVD) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison in Latest Trading; Share Response - vinanet.vn
Sat, 22 Aug 2026
IVVD|Invivyd Inc|Price:0.997|Chg%:+0.046 - TradingKey
Fri, 21 Aug 2026
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
Fri, 21 Aug 2026
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 19 Aug 2026
Invivyd Stock (IVVD) Opinions on Upcoming Phase 3 Results - Quiver Quantitative
Tue, 18 Aug 2026
Invivyd (IVVD) CCO’s 40,780-share stock sale runs under 10b5-1 plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 295 (M) |
| Shares Float | 208 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 86.4 (%) |
| Shares Short | 27,800 (K) |
| Shares Short P.Month | 27,440 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | -183.9 % |
| Operating Margin | -320.8 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -95.9 % |
| Qtrly Rev. Growth | 21.2 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -108 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -3.05 |
| PEG Ratio | 0 |
| Price to Book value | 1.3 |
| Price to Sales | 4.75 |
| Price to Cash Flow | -2.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|